Quick Answer
Phathom Pharmaceuticals, Inc. reported Net Income Loss of -$221.25 million for the year ending 2025.
- Phathom Pharmaceuticals, Inc. showed an increase of +33.8% in Net Income Loss from 2024 to 2025.
- This data is from Phathom Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$254.0 thousand | Q2 2018: -$260.0 thousand | Q3 2018: -$290.0 thousand | Q4 2018: -$484.0 thousand | Q1 2019: -$1.25 million | Q2 2019: -$87.76 million | Q3 2019: -$68.11 million | Q4 2019: -$98.01 million | Q1 2020: -$20.14 million | Q2 2020: -$21.10 million | Q3 2020: -$34.11 million | Q4 2020: -$53.72 million | Q1 2021: -$34.84 million | Q2 2021: -$36.55 million | Q3 2021: -$36.66 million | Q1 2022: -$40.67 million | Q2 2022: -$50.92 million | Q3 2022: -$51.09 million | Q1 2023: -$37.81 million | Q2 2023: -$40.97 million | Q3 2023: -$43.24 million | Q1 2024: -$82.85 million | Q2 2024: -$91.45 million | Q3 2024: -$85.58 million | Q1 2025: -$94.32 million | Q2 2025: -$75.81 million | Q3 2025: -$29.97 million.
- Over the full 8 years of available data (2018 to 2025), Phathom Pharmaceuticals, Inc.'s Net Income Loss has declined by 17,077.6%.
- Historical annual values: Fiscal year 2025: -$221.25 million | Fiscal year 2024: -$334.33 million | Fiscal year 2023: -$201.59 million | Fiscal year 2022: -$197.72 million | Fiscal year 2021: -$143.88 million | Fiscal year 2020: -$129.07 million | Fiscal year 2019: -$255.13 million | Fiscal year 2018: -$1.29 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: